Applications of D-3-Chlorophenylalanine in Industrial Manufacturing

D-3-Chlorophenylalanine serves as a specialized chemical intermediate across multiple industrial sectors involving complex synthesis workflows. As a manufacturer, we support pharmaceutical active ingredient development, diagnostic reagent production, fine chemical synthesis, and advanced materials science operations. Each application scenario outlined below reflects established and mature downstream manufacturing paths.

1. Pharmaceutical API Intermediate Synthesis

Pharmaceutical manufacturers use D-3-Chlorophenylalanine as a key chiral building block in the synthesis of various APIs, especially within the non-proteinogenic amino acid segment. The compound enters the synthetic route during the enantioselective construction of active pharmaceutical ingredients used to treat neurological disorders and certain cancers. Careful control of both isomeric purity and residual solvent levels forms part of the GMP compliance necessary for this sector. Formulations may require adjustment of reactant ratios based on the final API molecular structure and purity requirements.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) General Chapters Specific for Amino Acids
• European Pharmacopoeia (Ph. Eur.) 2.2.46 Chiral Chromatography
• Chinese Pharmacopoeia (ChP) Section on Chiral Raw Materials

Typical usage ratio

• 0.95–1.10 molar equivalents per reaction batch, adjusted for target molecule yield and selectivity

Downstream process integration

• Supplied as a crystalline solid directly charged to chiral amide coupling or reductive amination steps in multi-step API synthesis

Final product types

• Central Nervous System (CNS) medications
• Peptidomimetic chemotherapeutics
• Pharmaceutical chiral intermediates for further transformation
• Small-molecule receptor antagonists

2. Peptide Synthesis Reagents

Custom peptide manufacturers incorporate D-3-Chlorophenylalanine into synthetic peptide chains intended for R&D and clinical diagnostic use. The raw material enables specific incorporation of halogenated phenylalanine residues, imparting desired biodistribution and stability characteristics. Production batches must comply with international peptide manufacturing standards, with particular focus on traceability and contaminant control. Batch-specific ratios depend heavily on the peptide’s sequence, target yield, and required purity profile.

Industry compliance standards

• ISO 9001:2015 Quality Management for Peptide Manufacturing
• FDA 21 CFR Part 210/211 Current Good Manufacturing Practice for Finished Pharmaceuticals
• ICH Q3A/B Impurities in New Drug Substances/Products
• APIC Guidance on Good Distribution Practice for Pharmaceutical Starting Materials

Typical usage ratio

• Used as the designated amino acid monomer at 1 equivalent per iteration during solid-phase peptide synthesis cycles

Downstream process integration

• Introduced during automated or manual SPPS cycles following resin loading and Fmoc-deprotection steps

Final product types

• Synthetic research peptides for biomedical assays
• Labelled peptides for receptor binding studies
• Diagnostic bioactive peptides for ELISA or LC-MS detection
• Reference peptides supplied to pharmaceutical QC labs

3. Fine Chemicals for Agrochemical Research

Specialty fine chemical manufacturers integrate D-3-Chlorophenylalanine into the design and synthesis of potential agrochemical actives, including candidates for herbicide and pesticide development. The halogenated aromatic ring structure of the compound supports bioactivity modeling and targeted SAR studies. Compliance with national and international chemical safety guidelines applies, particularly regarding compound handling, waste, and workplace exposure. The raw material concentration varies based on early-stage screening versus scale-up of active ingredient leads.

Industry compliance standards

• OECD Guidelines for the Testing of Chemicals Section 1: Physical-Chemical Properties
• REACH Regulation (EC 1907/2006) Concerning Registration, Evaluation, Authorisation and Restriction of Chemicals
• ISO 17034 for Reference Material Producers (where applicable)
• GHS (Globally Harmonized System) chemical labeling standards

Typical usage ratio

• 0.5–2.0 molar equivalents, based on reaction pathway and target agrochemical scaffold type

Downstream process integration

• Charged at the initial synthetic building block step or as a halogen-unit donor in multi-component coupling reactions

Final product types

• Research-grade agrochemical scaffolds
• Candidate pesticides for greenhouse bioassay
• SAR reference compounds
• Chemical standards for analytical labs

4. In Vitro Diagnostic (IVD) Reagent Manufacturing

IVD reagent formulators employ D-3-Chlorophenylalanine in the preparation of enzyme substrates and calibration standards required for amino acid metabolism assays. The compound’s defined stereochemistry ensures traceability in clinical biochemical diagnostics. Compliance with in vitro diagnostic medical device regulation and traceability standards is essential to guarantee patient safety and laboratory reliability. The input amount is closely matched to the desired calibration curve range, depending on kit configuration.

Industry compliance standards

• IVDR (EU) 2017/746 Regulation on In Vitro Diagnostic Medical Devices
• ISO 13485:2016 Medical Devices—Quality Management Systems
• CLSI C62-A Liquid Chromatography Methods for Clinical Laboratories
• FDA 21 CFR 820 Quality System Regulation for Medical Devices

Typical usage ratio

• 1–10 mg per individual batch, precisely weighed to match assay specification

Downstream process integration

• Dissolved or pre-mixed during IVD buffer and substrate formulation prior to sterile filtration and filling

Final product types

• Clinical amino acid quantification kits
• Enzyme activity assay standards
• Calibration solutions for LC-MS or HPLC systems
• Reference materials for hospital biochemistry analyzers

5. Research-Grade Chiral Chemical Building Blocks

Advanced materials and specialty chemical laboratories use D-3-Chlorophenylalanine when exploring asymmetric synthesis, drug discovery tool compounds, and structure-activity relationship modeling. The consistent supply of enantiomerically pure material is critical for reproducible research results, and documentation must align with academic or industry quality expectations. Usage concentration is determined by experimental protocol, target molecule, and the type of chiral scaffold under investigation.

Industry compliance standards

• ISO 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories
• GLP (Good Laboratory Practice, OECD Principles)
• REACH Annex XVII (where applicable)
• Material Safety Data Sheet (MSDS) provision following GHS guidelines

Typical usage ratio

• 10–100 µmol per reaction, variable per synthetic design and analytical objectives

Downstream process integration

• Reacted in the initial condensation, alkylation, or cyclization steps of custom chiral compound synthesis

Final product types

• Chiral ligands for organometallic catalysis studies
• Tool compounds for receptor-ligand exploration
• Novel amino acid derivatives for structure-activity relationship (SAR) profiling
• Intermediate standards for analytical method development